Merck gains EU backing after 26% kidney cancer risk reduction
Merck (MRK) received a positive EU recommendation for WELIREG combined with lenvatinib to treat advanced kidney cancer, based on a 26% risk reduction in disease progression or death. The Phase 3 trial showed a 53.1% response rate for the combination. The European Commission's final decision is expected within two months. WELIREG sales grew 58% to $307M in Q3 2026.
How this was made
The 30-second read
Why it matters
The EU recommendation could unlock a large market, but final authorization is still pending, creating a near‑term catalyst.
Market read
First‑time EU regulatory endorsement for a major oncology drug could drive MRK stock higher pending final approval.
What to watch
Overall survival benefit was not statistically significant, which may temper investor enthusiasm
Background
Merck recently received US FDA approval for the same combo and reported a 58% sales increase in Q3 2026.
Ticker impact
EU CHMP issued a positive recommendation for Merck's belzutifan/lenvatinib combo for advanced renal cell carcinoma.
likely upside as market prices in potential EU approval and expanded market opportunity
First report of a favorable EU regulatory opinion for a new oncology combo; approval could add significant revenue and diversify MRK's pipeline.
Market effects
strengthens the oncology/renal‑cell‑carcinoma segment and may spur competitor pipeline activity
supports European biotech/oncology market sentiment and could boost related stocks
adds to global pharma growth narrative as a new HIF‑2α inhibitor gains foothold
Counterpoint
EU approval is not guaranteed; the European Commission could reject the product, limiting upside
Key entities
- companyMerck & Co.
US‑listed pharmaceutical company (ticker MRK) developing the belzutifan/lenvatinib combo.
- regulatorEuropean Medicines Agency (EMA)
EU regulatory body that issued the positive CHMP opinion.
